Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact
 September 12, 2013

Rational Design Of Modified Release Dosage Forms: From Pharmacokinetic Targets Through Technology Selection

Speakers for this Event:
  • Chris Craig, Director, Dosage Form Product Development, Bend Research Inc.  Learn More
  • Brett Caldwell, Ph.D., Director, Formulation Science, Bend Research Inc.  Learn More
  • During this webinar the presenters will discuss:

    •  Wide array of scalable dosage form technologies available:
  • Tablet vs Multiparticulates (pediatric, geriatric, high dose)
  • Continuous release (Zero order, First order) vs. Pulsatile
        (taste masking, enteric, delayed)
    • Matching technology strengths with API properties: Highly soluble APIs to Solubilized forms
    • Bringing all of the choices together through biological modeling

    Senior level executives working with dosage forms for pharmaceutical and biotechnology companies worldwide


    Chris Craig, Director, Dosage Form Product Development, Bend Research Inc. 

    Chris Craig is a Director of Dosage Form Product Development at Bend Research Inc. His expertise spans physical chemistry, process and pharmacokinetic modeling, engineering design, formulation and process development and scale up. His knowledge in the areas of spray-dried dispersion fundamentals and dosage forms supports a variety of client projects. He has developed immediate and modified release dosage forms, involving dry granulation, direct compression, particle size reduction, cosmetic and functional pan coating, and laser-drilling.

    Mr. Craig joined Bend Research in 1998 and holds a B.S. in chemical engineering from the University of Rochester.

    Brett Caldwell, Ph.D., Director, Formulation Science, Bend Research Inc. 

    Dr. W. Brett Caldwell is a Director of Formulation Science at Bend Research. His current responsibilities include leading client compound specific and technology development programs involving solubilization, modified release dosage forms, and inhalation. He has significant project based experience working with immediate release and controlled release solid dosage form formulations of solubilized and crystalline drug forms, relying on fundamental knowledge of solid state physical chemistry, crystallization, and pharmacokinetics.

    Dr. Caldwell joined Bend Research in 1999 after postdoctoral research at the University of California Berkeley. He earned his M.S. and Ph.D. degrees in inorganic chemistry from Northwestern University after receiving his bachelor's degree from Indiana's Wabash College. He is a co-inventor on 3 U.S. patents and patent applications and has written and published 13 articles.


    Bend Research is a leading independent scientific development and manufacturing company. For more than 35 years, its multidisciplinary teams have pioneered and advanced technologies to solve its clients’ most challenging technical problems.

    Bend Research has numerous capabilities to support the advancement of promising drug candidates from conception through commercialization. These include formulation and dosage-form support, process development and optimization, and cGMP manufacturing. It is a leader in novel drug-delivery technologies including spray-drying, hot-melt extrusion, and controlled release, and has expertise in inhalation and biotherapeutics development. The company employs more than 250 people and has six state-of-the-art facilities located in Bend, Ore.

    For information about the recorded archive for this event contact Xtalks at (416) 977-6555 ext 371, or email register@xtalks.com

    Share this:
    Copyright © 2016-2017 Honeycomb Worldwide Inc.